The valuable effects of Anzer bee products against the gliclazide-induced damage on human cell viability
DOI:
https://doi.org/10.71336/jabs.1507Keywords:
Cell viability, drug, hTERT-HPNE, Anzer honey, apoptosisAbstract
The studies on the benefits of natural products are still up to date around the world. The drugs are powerful agents for the treatment of the diseases, but the long-term use of the drugs may develop clinically unnoticeable side effects. They can cause damage at the cellular level and the cell viability can be affected. This status can lead to the development of some new diseases or cancer which is the most feared. We investigated the harmful effects of a frequently used antidiabetic drug gliclazide, on Healthy Human Pancreatic Cell “hTERT-HPNE” and aimed to improve these harmful effects with the special natural products of Anzer Plateau bees in Eastern Black Sea Region of Turkey. The cytotoxic and genotoxic effects of the drug gliclazide were investigated using different tests such as MTT, Flow Cytometry-Apoptosis. Anzer honey, pollen and propolis were analyzed by G/C-MS. The decrease in cell viability at all concentrations of the drug gliclazide was statistically significant compared to the negative control (p<0.05). A statistically significant decrease in gliclazide-induced apoptosis was detected with the addition of Anzer honey, pollen and propolis to hTERT-HPNE cells (p<0.05). Anzer honey, pollen and propolis maintained cell viability and healed the damage caused by the drug, This study may contribute to other studies testing the healing properties of natural products at cellular level.
References
REFERENCES
1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, et al. (2019): Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Research and Clinical Practice, 157:107843
2. Chaturvedi R, Desai C, Patel P, Shah A, Dikshit RK. (2018): An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus. Perspect Clin Res., 9: 15–22.
3. Evans JL, Goldfine ID, Maddux BA, Grodsky GM.(2002): Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev., 23: 599–622.
4. Rustenbeck I, Baltrusch S, Tiedge M.(2010): Do insulinotropic glucose–lewering drugs do more harm than good? The hypersecretion hypothesis revisited. Diabetologia, 53: 2105–2111.
5. El-Seedi HR, Eid N, Abd El-Wahed AA, Rateb ME, Afifi HS, et al. (2022): Honey Bee Products: Preclinical and Clinical Studies of Their Anti-inflammatory and Immunomodulatory Properties. Front Nutr.,3:8:761267. doi: 10.3389/fnut.2021.761267.
6. Giampieri F, Quiles JL, Cianciosi D, Forbes-Hernandez TY, Orantes-Bermejo J, et al. (2022): Bee Products: An Emblematic Example of Underutilized Sources of Bioactive Compounds. J. Agric. Food Chem., 70: 6833–6848.
7. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, et al. (2004): GUIDE study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation, 34: 535–542.
8. Louveaux J, Maurizio A, Vorwohl G. (2015): Methods of melissopalynology. Bee World, 59: 139-157.
9. Ulbricht C, Conquer J, Giese N, Singh Khalsa KP, Sklar J, et al. (2005): An evidence based systematic review of bee pollen by the natural standard research collaboration. J Dietary Suppl., 6: 290-312.
10. Erdoğan Y, Dodoloğlu A. (2005): Importance of Pollen in Life of Honeybee (Apis meelifera L.) Colonies. Uludağ Bee Journal, 5: 79-84.
11. Giovannucci E, Harlan DM, Archer MA, Bergenstal RM, Gapstur SM, et al. (2010): Diabetes and cancer: a consensus report. Diabetes Care, 33: 1674-1685.
12. Wild SH. (2011): Diabetes, treatments for diabetes and their effect on cancer incidence and mortality: attempts to disentangle the web of associations. Diabetologia, 54: 1589-1592.
13. Gul OO, Cinkilic N, Gul CB, Cander S, Vatan Ö, et al. (2013): Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: A cross-sectional, observational pilot study. Mutat Res.,757: 31-35.
14. Kasurka CB, Elbistan M, Atmaca A, Atlı Şekeroğlu Z. (2019): In vitro cytogenetic assessment and comparison of vildagliptin and sitagliptin. Cytotechnology, 71: 1063-1077.
15. Khan HM, Nawaz H, Aerooj H, Sharif A. (2021): Genotoxic and cytotoxic assessment of sitagliptin and simvastatin alone and in combination. Pak J Pharm Sci., 34: 1939-1944.
16. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. (2009): Sulphonylureas and Cancer: A Case-Control Study. Acta Diabetol., 46: 279–284.
17. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin. (2006): Diabetes Care, 29: 254–258.
18. Currie CJ, Poole CD, Gale EA. (2009): The Influence of Glucose-Lowering Therapies on Cancer Risk in Type 2 Diabetes. Diabetologia, 52: 1766–1777.
19. Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI. (2017): Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes Among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. Cancer Res, 77: 6033–6041.
20. Chen Y, Du L, Li L, Ma J, Geng X, et al. (2017): Cancer Risk of Sulfonylureas in Patients With Type 2 Diabetes Mellitus: A Systematic Review. J Diabetes, 9: 482–494. 21. Zhu B, Qu S. (2022): The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms. Front Endocrinol., 11(13):800995
22. Dankner R, Roth J. (2020): More recent, better designed studies have weakened links between antidiabetes medications and cancer risk. Diabet Med, 37: 194-202.
23. Bobis O, Mărghitaș LA, Dezmirean D, Morar O, Bonta V, Chirila F.(2010): Quality Parameters and Nutritional Value of Different Commercial Bee Products. Bull Univ Agric Sci Vet Med Cluj-Napoca Anim Sci Biotechnol, 67: 1-2.
24. Zullkiflee N, Taha H, Abdullah NA, Hashim F, Usman A.(2022): Antibacterial and antioxidant activities of ethanolic and water extracts of stingless bees Tetrigona binghami, Heterotrigona itama, and Geniotrigona thoracica propolis found in Brunei. Philippine Journal of Science, 151: 1455–1462.
25. Özdemir Ö, Çöl Z, Ertürk Ö. (2023): Efficacy of Bee Products (Anzer Honey, Pollen and Propolis) in Detection and Healing of Damage Induced by Antidiabetic Drug Vildagliptin/Metformin Hydrochloride in Healthy Human Pancreatic Cells: Cytotoxic, Genotoxic and Biochemical Studies. Current Medical Science, 43: 1173-1182.
26. Garcia C, Andersen CJ, Blesso CN. (2023): The Role of Lipids in the Regulation of Immune Responses. Nutrients,15(18): 3899.
27. Boden G. (2011): Obesity, insülin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes., 18: 139–143.
28. Biswas P, Datta C, Rathi P, Bhattacharjee A. (2022): Fatty acids and their lipid mediators in the induction of cellular apoptosis in cancer cells. Prostaglandins Other Lipid Mediat., 160:106637.
29. Sawicka D, Car H, Borawska MH, Nikliński J.(2012): The anticancer activity of propolis. Folıa Hıstochemıca et Cytobıologıca, 50: 25–37.
30. Khan AA, Alanazı AM, Jabeen M, Chayhan A, Abdelhameed AS. (2013): Design, Synthesis and In Vitro Anticancer Evaluation of a Stearic Acid-based Ester Conjugate. Anticancer Research, 33 (6): 2517-2524.
31.Wang X, Zhang C, Bao N. (2023): Molecular mechanism of palmitic acid and its derivatives in tumor progression. Front Oncol., 9,13:1224125.
32. Anantharaju PG, Reddy BD, Padukudru MA, Chitturi MK, Vimalambike MG, Madhunapantula SV. (2017): Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC). Cancer Biol Ther.,18(7): 492–504.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of Applied Biological Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
